Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES
Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.
Source: onclive.com